Qingying Huakang Secures Tens of Millions RMB in Series A Funding to Advance Commercialization of Innovative Medical Imaging Solutions

VCBeat (WeChat ID: vcbeat) has learned that Beijing Qingying Huakang Technology Co., Ltd. (“Qingying Huakang”), an innovative provider of medical imaging solutions, recently completed a Series A financing round amounting to tens of millions of RMB.This round of financing was led by Zongheng Capital.It is reported that the funds from this round of financing will primarily be allocated to two areas. First, increasing the application of innovative technologies such as artificial intelligence to drive product upgrades and iterations. Second, initiating the registration process for Class III medical devices to establish clinical diagnosis and treatment pathways.

Qingying Huakang was incubated by the Biomedical Imaging Research Center at Tsinghua University, focusing on the development of innovative medical imaging solutions. Its founder, Dr. Li Rui, is a researcher at the Biomedical Imaging Center of Tsinghua University. Leveraging nearly 30 years of expertise in technology development, pathological validation, clinical trials, and data accumulation in this field, Dr. Li’s team co-founded Qingying Huakang with industry experts in 2016.Translating the research achievements of Tsinghua University's Biomedical Imaging Research Center into products, providing high-resolution magnetic resonance imaging solutions for the diagnosis and treatment of cerebrovascular diseases.

Since its inception, Qingying Huakang has established collaborations with numerous R&D institutions, Grade-A tertiary hospitals, medical equipment manufacturers, health examination centers, third-party imaging centers, and AI-based medical imaging companies. Meanwhile, it has been certified as both a Zhongguancun High-Tech Enterprise and a National High-Tech Enterprise, and has obtained multiple invention and utility model patents. Currently, its products have been sold to over 100 clinical hospitals across China, facilitating scientific research and clinical applications in high-resolution magnetic resonance imaging (MRI).

Cardiovascular and cerebrovascular diseases are the leading cause of death in humans. The "Report on Cardiovascular Health and Diseases in China 2020" shows that the prevalence of cardiovascular and cerebrovascular diseases in China continues to rise, with approximately 330 million affected individuals.

However, cerebrovascular imaging techniques routinely used in clinical practice, such as carotid ultrasound, transcranial Doppler (TCD), magnetic resonance angiography (MRA), computed tomography angiography (CTA), and digital subtraction angiography (DSA), suffer from significant limitations: they focus solely on the vessel lumen, lack detailed lesion information, make it difficult to identify vulnerable plaques, and fail to provide precise evidence for clinical diagnosis and treatment.

Advances in imaging and artificial intelligence have opened up new possibilities for the prevention, diagnosis, and treatment of cardiovascular and cerebrovascular diseases, giving rise to high-resolution magnetic resonance imaging (MRI) protocols. It is understood that Qingying Huakang has integrated professional imaging sequences, high signal-to-noise ratio (SNR) imaging coils, AI-based interpretation algorithms, and imaging workstations into a comprehensive one-stop solution spanning from image acquisition to report generation, thereby making clinical applications more standardized and efficient.

The integration of medical imaging and artificial intelligence holds significant application value and commercialization potential.

The 2021 Medical AI Report, “Medical AI’s Sprint and Transformation on the Eve of IPO,” offers a clear view of the commercial momentum behind imaging AI. Based solely on publicly available bidding data, imaging AI solutions procured by hospitals accounted for 23.9% of all smart healthcare applications.

The expansion of market demand has further driven the in-depth development of AI in medical imaging. Since the release of the “Key Points for Approval of Medical Device Software Assisted by Deep Learning” in June 2019, the National Medical Products Administration (NMPA) has progressively standardized reference databases and training datasets for certain artificial intelligence-enabled medical devices, thereby accelerating the review and approval process for such products. Currently, the construction of foundational platforms for medical imaging has become increasingly robust. However, at the stage of clinical application of medical imaging AI technologies, there remains considerable room for improvement in meeting actual clinical needs.

Dr. Li Rui, the company's founder, told VCBeat:“To maximize the impact of innovative research outcomes and enhance the alignment between products and clinical needs, integrating emerging technologies into clinical diagnostic and treatment protocols is a crucial step. Identifying precise clinical problems, conducting exploration tailored to clinical scenarios, and implementing end-to-end product development are key to ensuring the practical deployment of AI technology and overcoming the final barriers to clinical adoption. We believe that information extraction must begin at the imaging stage—spanning from signal acquisition and reconstruction to backend image processing algorithms. Only through such end-to-end innovation can clinically meaningful imaging information be generated, thereby improving the standard of clinical diagnosis and treatment. This is the rationale behind our commitment to end-to-end product innovation.”

From Qingying Huakang’s perspective, if relevant information is not captured during image acquisition, no amount of subsequent processing can yield the most valuable insights for disease diagnosis and treatment. Therefore, its solutions place significant emphasis on the research and development of imaging methodologies.

Currently, Qingying Huakang has completed the research and development of high-resolution magnetic resonance imaging solutions and obtained two Class II medical device registration certificates.Moving forward, the company will adopt a clinical problem-oriented approach, integrating more innovative technologies into its products to drive the iteration and advancement of innovative medical imaging solutions.

As resources continue to expand, Qingying Huakang will initiate the registration process for Class III medical devices. Through end-to-end innovation and application, it aims to establish a closed loop spanning from clinical needs to product development and ultimately to clinical implementation.Establish closer collaborations with relevant enterprises to enhance the application standards and capabilities of medical devices and medical imaging, thereby promoting the broader clinical adoption of Qingying Huakang’s solutions.

Wang Hailong of Zongheng Capital remains bullish on Qingying Huakang, stating:“Medical imaging AI is currently entering a golden age of development. We believe that Qingying Huakang can leverage its artificial intelligence technology to help more patients, further empower industry development, and provide better services to hospitals and domestic manufacturers. Zongheng Capital focuses on technological innovation and the commercialization of scientific research achievements. Through our research and analysis, we consider Qingying Huakang to be an enterprise with leading advantages and strong momentum in the medical imaging AI sector, poised for significant future growth.”

In the future, Qingying Huakang will enhance its ability to rapidly translate basic research innovations into products by establishing a technology transfer platform, thereby launching more innovative imaging solutions that meet clinical needs. Meanwhile, leveraging its open hardware and software development platform, Qingying Huakang will integrate various advanced imaging solutions tailored to specific clinical applications. By collaborating with research institutes to establish streamlined intellectual property commercialization processes, the company aims to foster a win-win cooperative ecosystem and accelerate the translation of more scientific achievements. This approach aligns with Zongheng Capital’s mission, established at its founding in 2014, to drive the development of the real economy through financial investment, pursuing multi-win investments that benefit the nation, the public, enterprises, and investors alike.

Zongheng Capital Investment Co., Ltd. was jointly established by Wang Pu, founder of Allpku Management Consulting Group, along with its core management team and elite professionals from the investment industry. It serves as the sole investment platform within the Allpku Group. Founded in 1996, Allpku Management Consulting Group is the first management consulting firm registered in China. With management consulting at its core, the Group provides comprehensive services to enterprises through its business school and investment arms.

Zongheng Capital, established in 2014, is committed to becoming an equity investment fund management firm that delivers top-tier excess returns to its investors. The company has accumulated years of research and investment experience in hard technology sectors such as healthcare, robotics, and intelligent manufacturing. Leveraging the Group’s 19 business divisions and over 160 industry centers across more than 20 major cities in China, which have completed nearly 10,000 consulting cases, Zongheng Capital has built a multi-channel, multi-layered corporate resource database encompassing government agencies, industry associations, professional survey firms, and its proprietary survey network. The company maintains close exchanges and collaborations with prestigious institutions including Tsinghua University, Peking University, the Chinese Academy of Sciences, Renmin University of China, Cheung Kong Graduate School of Business, and CEIBS, while also engaging in in-depth cooperation with numerous renowned domestic and international industrial research institutes, industry associations, securities firms, and peers. Nearly a decade of dedicated expertise has laid a solid foundation for providing corporate financing and investment services, effectively ensuring the professionalism of Zongheng Capital’s products and services.